First Midwest Bank Trust Division lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 19.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 28,872 shares of the biopharmaceutical company’s stock after selling 7,033 shares during the period. First Midwest Bank Trust Division’s holdings in Gilead Sciences were worth $2,043,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of GILD. Wilsey Asset Management Inc. raised its stake in shares of Gilead Sciences by 2.7% in the first quarter. Wilsey Asset Management Inc. now owns 117,603 shares of the biopharmaceutical company’s stock worth $8,028,000 after buying an additional 3,042 shares during the period. Lawson Kroeker Investment Management Inc. NE raised its stake in shares of Gilead Sciences by 24.0% in the first quarter. Lawson Kroeker Investment Management Inc. NE now owns 120,888 shares of the biopharmaceutical company’s stock worth $8,211,000 after buying an additional 23,395 shares during the period. Gulf International Bank UK Ltd raised its stake in shares of Gilead Sciences by 1.3% in the first quarter. Gulf International Bank UK Ltd now owns 412,082 shares of the biopharmaceutical company’s stock worth $27,988,000 after buying an additional 5,100 shares during the period. Nexus Investment Management Inc. raised its stake in shares of Gilead Sciences by 7.7% in the first quarter. Nexus Investment Management Inc. now owns 253,166 shares of the biopharmaceutical company’s stock worth $17,195,000 after buying an additional 18,150 shares during the period. Finally, ANTIPODES PARTNERS Ltd raised its stake in shares of Gilead Sciences by 23.4% in the first quarter. ANTIPODES PARTNERS Ltd now owns 781,418 shares of the biopharmaceutical company’s stock worth $55,629,000 after buying an additional 148,226 shares during the period. 74.02% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences, Inc. (NASDAQ GILD) traded down 0.31% on Friday, hitting $73.79. The stock had a trading volume of 3,729,031 shares. The firm has a market cap of $96.36 billion, a price-to-earnings ratio of 8.01 and a beta of 1.21. The company’s 50-day moving average price is $72.97 and its 200 day moving average price is $68.86. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $82.07.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.11 by $0.45. The company had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s revenue for the quarter was down 8.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.08 EPS. Analysts expect that Gilead Sciences, Inc. will post $8.74 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.82%. Gilead Sciences’s dividend payout ratio is currently 22.58%.

TRADEMARK VIOLATION WARNING: This story was first reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The legal version of this story can be viewed at https://theolympiareport.com/2017/08/27/gilead-sciences-inc-gild-shares-sold-by-first-midwest-bank-trust-division.html.

Several research analysts have recently commented on GILD shares. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 price target for the company in a research report on Tuesday, May 2nd. BMO Capital Markets reissued a “hold” rating and issued a $76.00 price target (up from $75.00) on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Robert W. Baird reissued an “outperform” rating and issued a $87.00 price target on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $87.00 price target on shares of Gilead Sciences in a research report on Wednesday, May 3rd. Eleven analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $80.64.

In other news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the sale, the insider now owns 3,199,969 shares in the company, valued at approximately $227,197,799. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of Gilead Sciences stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total transaction of $355,300.00. Following the completion of the sale, the executive vice president now owns 102,988 shares of the company’s stock, valued at approximately $7,318,327.28. The disclosure for this sale can be found here. Insiders sold a total of 206,666 shares of company stock valued at $15,223,184 in the last quarter. 1.30% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.